Critical Contrast: RenovaCare (OTCMKTS:RCAR) versus Endologix (OTCMKTS:ELGX)

Share on StockTwits

RenovaCare (OTCMKTS:RCAR) and Endologix (NASDAQ:ELGX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.

Analyst Recommendations

This is a summary of recent ratings for RenovaCare and Endologix, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RenovaCare 0 0 0 0 N/A
Endologix 0 4 1 0 2.20

Endologix has a consensus target price of $18.50, suggesting a potential upside of 364.82%. Given Endologix’s higher possible upside, analysts plainly believe Endologix is more favorable than RenovaCare.

Insider & Institutional Ownership

77.9% of Endologix shares are held by institutional investors. 0.9% of RenovaCare shares are held by company insiders. Comparatively, 1.3% of Endologix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


This table compares RenovaCare and Endologix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RenovaCare N/A -18.54% -17.51%
Endologix -60.32% -120.57% -17.04%

Volatility and Risk

RenovaCare has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500. Comparatively, Endologix has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500.

Valuation and Earnings

This table compares RenovaCare and Endologix’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RenovaCare N/A N/A -$2.12 million N/A N/A
Endologix $156.47 million 0.45 -$79.71 million ($7.20) -0.55

RenovaCare has higher earnings, but lower revenue than Endologix.


Endologix beats RenovaCare on 6 of the 10 factors compared between the two stocks.

RenovaCare Company Profile

RenovaCare, Inc., a development-stage company, focuses on the acquisition, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System for spraying a patient's own skin stem cells onto burns and wounds for self-healing; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. The company was formerly known as Janus Resources, Inc. and changed its name to RenovaCare, Inc. in January 2014. RenovaCare, Inc. is based in Scottsdale, Arizona.

Endologix Company Profile

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Receive News & Ratings for RenovaCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovaCare and related companies with's FREE daily email newsletter.